These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9892135)

  • 1. The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells.
    Vauquelin G; Fierens FL; De Backer JP; Vanderheyden PM
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S15-7. PubMed ID: 9892135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
    Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
    Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
    Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
    Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
    Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
    Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors.
    Vanderheyden PM; Verheijen I; Fierens FL; DeBacker JP; Vauquelin G
    Pharm Res; 2000 Dec; 17(12):1482-8. PubMed ID: 11303957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
    Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
    Lambert DG; Champion HC; Kadowitz PJ
    Can J Physiol Pharmacol; 1998 Feb; 76(2):133-40. PubMed ID: 9635151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat.
    Champion HC; Bivalacqua TJ; Lambert DG; McNamara DB; Kadowitz PJ
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S101-3. PubMed ID: 9892149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells.
    Le MT; De Backer JP; Hunyady L; Vanderheyden PM; Vauquelin G
    Eur J Pharmacol; 2005 Apr; 513(1-2):35-45. PubMed ID: 15878707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells.
    Fierens F; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 Feb; 367(2-3):413-22. PubMed ID: 10079018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
    Ruan X; Purdy KE; Oliverio MI; Coffman TM; Arendshorst WJ
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S202-7. PubMed ID: 9892164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of saponin and filipin on antagonist binding to AT 1 receptors in intact cells.
    Verheijen I; Tourlousse D; Vanderheyden PM; Backer JP; Vauquelin G
    Biochem Pharmacol; 2004 Apr; 67(8):1601-6. PubMed ID: 15041477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T
    Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonist interaction with endogenous AT(1) receptors in human cell lines.
    Verheijen I; Vanderheyden PM; De Backer JP; Bottari S; Vauquelin G
    Biochem Pharmacol; 2002 Oct; 64(8):1207-14. PubMed ID: 12234601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
    Inada Y
    Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
    Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
    Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesangial AT1 receptors: expression, signaling, and regulation.
    Ardaillou R; Chansel D; Chatziantoniou C; Dussaule JC
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S40-6. PubMed ID: 9892139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K; Inada Y; Nishikawa K
    Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.